These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Agranulocytosis during multidrug therapy (MDT) of leprosy. Reeve P Lepr Rev; 1992 Mar; 63(1):82-3. PubMed ID: 1569822 [No Abstract] [Full Text] [Related]
23. Dapsone induced hypohaptoglobinemia in lepromatous leprosy patients. Sritharan V; Bharadwaj VP; Venkatesan K; Girdhar BK Int J Lepr Other Mycobact Dis; 1981 Sep; 49(3):307-10. PubMed ID: 7198620 [TBL] [Abstract][Full Text] [Related]
24. [Survey on the prevalence rate of dapsone-resistant leprosy in the Yangzhou district]. Li WZ; Ye GY; Wang HY; Tao MB; Ma B; Zhang YF Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Feb; 6(1):59-61. PubMed ID: 6238701 [No Abstract] [Full Text] [Related]
25. Unusual reaction to intramuscular sulfone in two leprosy patients in Malaysia. Laing AB Int J Lepr Other Mycobact Dis; 1980 Mar; 48(1):70. PubMed ID: 7189187 [No Abstract] [Full Text] [Related]
26. [Initial results of prospective controlled treatment trials in leprosy]. Pattyn SR Verh K Acad Geneeskd Belg; 1984; 46(3):207-19. PubMed ID: 6391013 [No Abstract] [Full Text] [Related]
27. Monitoring the regularity of self administration of dapsone by leprosy patients. Kumar A; Balakrishnan S Lepr India; 1982 Oct; 54(4):664-70. PubMed ID: 7183832 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases. Kundu SK; Hazra SK; Chaudhury S; Chatterjee B Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246 [TBL] [Abstract][Full Text] [Related]
30. Side-effects of Isoprodian compared with WHO-MDT in rural Nepal. van Brakel WH; Drever W Lepr Rev; 1993 Sep; 64(3):276-80. PubMed ID: 8231610 [No Abstract] [Full Text] [Related]
31. Chemotherapeutic trials in leprosy. 4. Dapsone (DDS) in low dosage in the treatment of lepromatous leprosy. A demonstration pilot study. Pettit JH; Rees RJ Int J Lepr Other Mycobact Dis; 1967; 35(2):140-8. PubMed ID: 5338958 [No Abstract] [Full Text] [Related]
32. Intramuscular injection of dapsone in therapy for leprosy: a new approach. Modderman ES; Huikeshoven H; Zuidema J; Leiker DL; Merkus FW Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):51-6. PubMed ID: 7061179 [TBL] [Abstract][Full Text] [Related]
33. Dapsone induced psychosis. Balkrishna ; Bhatia MS J Indian Med Assoc; 1989 May; 87(5):120-1. PubMed ID: 2600436 [No Abstract] [Full Text] [Related]
35. [Pilot-trial of treatment of leprosy by pig's thymosin combined with dapsone (author's transl)]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1981 Sep; 3(3):198-200. PubMed ID: 6459183 [No Abstract] [Full Text] [Related]
36. Rheumatoid arthritis: the effects of treatment with dapsone on hemoglobin. Grindulis KA; McConkey B J Rheumatol; 1984 Dec; 11(6):776-8. PubMed ID: 6520831 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of WHO regimens in the management of leprosy patients with G6PD deficiency. Mysore V; al-Suwaid AR Int J Lepr Other Mycobact Dis; 1999 Jun; 67(2):159-61. PubMed ID: 10472369 [No Abstract] [Full Text] [Related]
38. Hypersensitivity reaction to dapsone: report from Malaysia. Mohamed KN Lepr Rev; 1984 Dec; 55(4):385-9. PubMed ID: 6527602 [No Abstract] [Full Text] [Related]
39. Dapsone syndrome--a five year retrospective analysis. Kumar RH; Kumar MV; Thappa DM Indian J Lepr; 1998; 70(3):271-6. PubMed ID: 9801899 [TBL] [Abstract][Full Text] [Related]